Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class A

As of June 30, 2026, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class A carries a market capitalization of 48.53B, placing it among publicly traded companies globally. Its enterprise value stands at 48.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class A's next confirmed earnings release is scheduled for March 31, 2027.

As of June 30, 2026, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class A has 443.62M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class A maintains a current ratio of 3.42, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 121.08, while the 200-day moving average is 97.98.

As of June 30, 2026, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class A holds 1.01B in cash and equivalents against 693.49M in total debt, resulting in a net debt position of -627.77M. Total book value stands at 2.42B, with working capital of 1.20B providing operational flexibility.